Lumen Technologies hires Sean Alexander as head of Connected Ecosystems
CAMBRIDGE, MA— Blueprint Medicines Corp (NASDAQ:BPMC), a $5.6 billion market cap biotechnology company, has reported that its CEO, Kate Haviland, sold 16,151 shares of the company’s common stock on March 5, 2025. The transaction comes as InvestingPro data shows the stock has declined over 8% in the past week. The shares were sold at an average price of $88.80 each, totaling approximately $1.43 million. This transaction was conducted to cover tax withholding obligations related to the vesting of restricted stock units, as specified in the filing. Following this sale, Haviland retains ownership of 168,427 shares in the company. According to InvestingPro, analysts maintain a bullish outlook on BPMC with price targets ranging from $83 to $169, while the company’s Financial Health score is rated as "FAIR." Get access to 8 more exclusive ProTips and comprehensive analysis through InvestingPro’s detailed research reports.
In other recent news, Blueprint Medicines has made several significant announcements impacting its outlook. The company recently disclosed its fourth-quarter financials for 2024, aligning with consensus expectations. Additionally, Blueprint Medicines provided revenue guidance for Ayvakit for fiscal year 2025, estimating between $680 million and $710 million. Scotiabank (TSX:BNS) initiated coverage on Blueprint Medicines with a Sector Outperform rating and a price target of $150, highlighting the potential of the company’s systemic mastocytosis franchise and its promising pipeline, including drugs like elenestinib and BLU-808.
Stifel analysts maintained their Buy rating and $155 price target, addressing concerns about Ayvakit’s safety and affirming confidence in its clinical data. JMP Securities also reaffirmed its Market Outperform rating and a price target of $126, emphasizing the positive safety profile of Ayvakit as demonstrated in the PIONEER trial. Citizens JMP maintained a $125 price target, expressing optimism about Ayvakit’s sales potential, projected to reach $700 million by 2025.
Blueprint Medicines’ robust cash position, supported by an $80 million inflow from the acquisition of null Pharmaceuticals by GlaxoSmithKline (NYSE:GSK), enhances its financial stability. Analysts from various firms have shown confidence in the company’s growth trajectory, with potential for significant revenue from its systemic mastocytosis treatment and other drugs in its pipeline.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.